Syros Pharmaceuticals基本情况
Company Overview
Syros Pharmaceuticals, Inc. (SYRS) is a biopharmaceutical company focused on developing treatments for hematologic malignancies. Founded in 2011 and headquartered in Cambridge, Massachusetts, the company’s lead product candidates include Tamibarotene, SY-2101, and SY-5609, which are in various stages of clinical trials 86.
Shareholder and Capital Structure Analysis
As of recent data, Syros Pharmaceuticals has a total of 26.83 million shares outstanding, with a market capitalization of approximately $2.28 million 8. The company’s stock has experienced significant volatility, with a 52-week range between $0.0653 and $0.0949 8.
Operational Capability Analysis
In Q2 2024, Syros reported an operating income of -$27.416 million, which was better than the estimated -$30.7 million 97. The company’s financials indicate a challenging operational environment, with a negative EPS of -$0.16 and a net loss of -$6.4 million in its latest earnings report 64.
Competitive Analysis
Syros faces strong competition in the biopharmaceutical sector. Recent developments include the termination of collaborations with Incyte and Pfizer, which could impact its competitive positioning 5861. The company’s focus on niche hematologic treatments provides some differentiation, but its financial instability remains a concern.
Development Prospects
Syros is advancing its pipeline, with Tamibarotene in Phase III trials for myelodysplastic syndrome and Phase II for acute myeloid leukemia 86. However, the company’s ability to secure additional partnerships or funding will be critical for its long-term success.
Significant Events
Key recent events include the termination of its collaboration with Incyte in August 2023 58 and a significant stock price drop of 46.65% in March 2025 64. Additionally, Syros is expected to report its next earnings on March 25, 2025 86.
Company Overview Summary
Syros Pharmaceuticals is a biopharmaceutical company with a focus on hematologic malignancies. Despite a promising pipeline, the company faces financial challenges and competitive pressures. Its ability to secure partnerships and advance clinical trials will be crucial for future growth.
暂无评论内容